Tumor localization of CEA-containing human tumors in nude mice by means of monoclonal anti-CEA antibodies
✍ Scribed by Anders Hedin; Britta Wahren; Sten Hammarström
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- French
- Weight
- 663 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Three different monoclonal antibodies (mabs) directed against conformation‐dependent protein determinants in carcinoembryonic antigen (CEA) were evaluated for tumorimmunolocalization of CEA‐containing human tumors grown in nude mice. The antibodies were of high affinity and of the IgG~1~ subclass. They did not react with non‐specific cross‐reacting antigen (NCA), biliary glyco‐protein 1 (BGP 1) or orosomucoid. 10–20 μCi(1–2 μg) of ^131^I‐labelled mab was injected intraperitoneally into mice bearing heterografts of the CEA‐containing human tumor cell lines LS 174T, Detroit 562 or HT‐29 or into mice bearing grafts of the non‐CEA‐containing human tumor cell line RD. The concentration of radiolabelled mab in the tumor compared with the mean concentration in the mouse increased up to day 4 after injection. In contrast, the concentration ratios of radioactivity in the other tissues decreased with time. Excellent tumor localization was obtained with mab 38SI in mice bearing LS 174T tumors. The concentration of radioactivity (cpm/g) tissue wet weight) was 24–390 times higher in the tumor than in the muscle. The difference between tumor and liver and between tumor and blood was 4–89 times and 2–25 times, respectively. A mean value of 40% of the total radioactivity in the mouse at day 4 was localized to the tumor. Mab 38SI also showed positive tumor localization in mice carrying Detroit and HT‐29 tumors. Means of 22% and 18% of the total radioactivity in the mouse at day 4 were found in these tumors, respectively. Mab 38SI was, however, not enriched in the tumor of mice bearing the non‐CEA‐containing sarcoma RD. Furthermore, when LS 174T tumor‐bearing mice were injected with normal mouse IgG, no enrichment of radioactivity in the tumor was seen. Positive tumor localization with mab 48 was obtained while mab 9 was not enriched in the tumor. Scanning pictures of LS 174T‐grafted mice on day 4 after injection of ^131^I‐mab 38SI showed a definite radioactive spot corresponding to the tumor and in addition a spot corresponding to the liver or the heart.
📜 SIMILAR VOLUMES
A syngeneic anti-idiotype monoclonal antibody (MAb) (CM-I I) directed against an anti-carcinoembryonic antigen (CEA) murine MAb (NP-4) was evaluated as a second antibody (SA) to promote the rapid clearance of radiolabeled NP-4 from the blood. Initial studies confirmed that CM-I I IgG removed l3Il-NP
## BACKGROUND. The immunoglobulin G 1 (IgG 1 ) monoclonal
Radioimmunotherapy in humans is limited by toxicity to normal tissues, caused by circulating radio-antibody. Second antibody directed against the first (anti-tumor) antibody accelerates clearance of first antibody from normal tissues, and may thus improve the therapeutic ratio. The effect of second
Background. Many studies have demonstrated synergistic interaction between hyperthermia and radiation. This study was undertaken to determine whether hyperthermia could enhance the effect of radioimmunotherapy (RIT) in the treatment of human colon adenocarcinoma xenografts in nude mice. The experim
Endoglin (CD105), which is a component of the TGF- receptor complex, is highly expressed at the surface of proliferating human endothelial cells such as those of tumor vessels. In the present study, we tested the antitumor efficacy of 125 I-labeled anti-endoglin monoclonal antibodies (MAbs), SN6f a